U.S. Patent & Trademark Office has issued U.S. Patent # 7,132,570 (the ‘570 patent) against the patent application number 10/539,918 filed by Cephalon France for polymorphic form of laevorotatory enantiomer of modafinil or armodafinil, the active ingredient in NUVIGIL tablets which is pending for approval with the US Food and Drug Administration. The ‘570 patent will run out its patent term on December 18, 2023. NUVIGIL is improved version of Cephalon’s blockbuster drug PROVIGIL.
Thursday, November 09, 2006
Cephalon received U.S. Patent for Armodafinil Polymorphic Form
U.S. Patent & Trademark Office has issued U.S. Patent # 7,132,570 (the ‘570 patent) against the patent application number 10/539,918 filed by Cephalon France for polymorphic form of laevorotatory enantiomer of modafinil or armodafinil, the active ingredient in NUVIGIL tablets which is pending for approval with the US Food and Drug Administration. The ‘570 patent will run out its patent term on December 18, 2023. NUVIGIL is improved version of Cephalon’s blockbuster drug PROVIGIL.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment